Related Experiment Video
Updated: Mar 28, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
DAB2IP in cancer
Liang Liu1,2, Cong Xu3, Jer-Tsong Hsieh4
1Tongji Cancer Research Institute, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Abstract:
DOC-2/DAB2 is a member of the disable gene family that features tumor-inhibiting activity. The DOC-2/DAB2 interactive protein, DAB2IP, is a new member of the Ras GTPase-activating protein family. It interacts directly with DAB2 and has distinct cellular functions such as modulating different signal cascades associated with cell proliferation, survival, apoptosis and metastasis. Recently, DAB2IP has been found significantly down regulated in multiple types of cancer. The aberrant alteration of DAB2IP in cancer is caused by a variety of mechanisms, including the aberrant promoter methylation, histone deacetylation, and others. Reduced expression of DAB2IP in neoplasm may indicate a poor prognosis of many malignant cancers. Moreover, DAB2IP stands for a promising direction for developing targeted therapies due to its capacity to inhibit tumor cell growth in vitro and in vivo. Here, we summarize the present understanding of the tumor suppressive role of DAB2IP in cancer progression; the mechanisms underlying the dysregulation of DAB2IP; the gene functional mechanism and the prospects of DAB2IP in the future cancer research.
Insights
DAB2IP, a tumor-suppressing protein, is frequently downregulated in cancers due to epigenetic changes. Its reduced expression indicates poor prognosis, but DAB2IP offers potential for targeted cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- DAB2IP (Disabled-2 Interacting Protein) is a Ras GTPase-activating protein family member.
- It interacts with DAB2 and regulates cell proliferation, survival, apoptosis, and metastasis.
- DAB2IP exhibits tumor-inhibiting activity and is part of the disable gene family.
Purpose of the Study:
- To review the tumor-suppressive role of DAB2IP in cancer progression.
- To elucidate the mechanisms of DAB2IP dysregulation in cancer.
- To discuss DAB2IP's functional mechanisms and therapeutic potential.
Main Methods:
- Literature review and synthesis of current research on DAB2IP.
- Analysis of molecular mechanisms underlying DAB2IP dysregulation (e.g., promoter methylation, histone deacetylation).
- Evaluation of DAB2IP's role in various cancer types based on existing studies.
Main Results:
- DAB2IP is significantly downregulated in multiple cancer types.
- Aberrant expression is linked to epigenetic alterations like aberrant promoter methylation and histone deacetylation.
- Reduced DAB2IP expression correlates with poor prognosis in malignant cancers.
Conclusions:
- DAB2IP acts as a crucial tumor suppressor in cancer progression.
- Epigenetic modifications are key drivers of DAB2IP downregulation in neoplasms.
- DAB2IP represents a promising target for novel cancer therapies due to its demonstrated ability to inhibit tumor growth.
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:11IP3/DAG Signaling Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...